Search
bevirimat
Investigational agent
Indications:
- adjunctive treatment of HIV1 infection*
* resistance is high:
- 32% of treatment-naive patients
- 25% of patients with resistance to reverse transcriptase inhibitors
- 45% among patients with resistance to HIV protease inhibitors
Mechanism of action:
- HIV integrase inhibitor (similar to raltegravir)
Interactions
drug adverse effects of antiretroviral agents
Related
raltegravir (Isentress, RAL)
General
antiretroviral agent
References
- Verheyen J et al.
High prevalence of bevirimat resistance mutations in protease
inhibitor-resistant HIV isolates.
AIDS 2009 Nov 18
PMID: 19926962
http://tinyurl.com/yej8u4w